Pfizer — 36th Annual J.P. Morgan Healthcare Conference 2018

5 slides from Pfizer's conference presentation, Jan 8, 2018

Slide 1: A New Era of Pfizer R&D Productivity
JP Morgan Healthcare Conference A New Era of Pfizer R&D Productivity Mikael Dolsten, M.D., Ph.D. President, Worldwide R&D January 8, 2018
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes forward-looking statements about, among other things, our in-line products and product candidates, including anticipated regulatory submissions, data read-outs, approvals, performance, timing of exclusivity, potential benefits of Pfizer's product
Slide 3: Step Change in Pfizer R&D Productivity
Step Change in Pfizer R&D Productivity Actual and potential blockbuster approvals (as of January 2018) Up to 15 in 5 Years* 1. IO-IO: Mono/Combo 2. IO-Targeted / IO-Chemo 3. Targeted Cancer Agents (Collective) (talazoparib, lorlatinib, dacomitinib, glasdegib) Oncology 4. Ibrance® Intermediate/High R
Slide 4: Potential 2018 Milestones
Potential 2018 Milestones LATE STAGE Xtandi® talazoparib Xeljanz® lorlatinib nmCRPC PROSPER EMBRACA Ulcerative Colitis NSCLC 2L Submission (US/EU) Submission (US/EU) Action Date (US/EU) Action Date (US) Bavencio® Vyndaqel® rivipansel tanezumab NSCLC 2L Cardiomyopathy Sickle Cell OA/CLBP Pain Phase 3
Slide 5: Discussion
Discussion